Hostname: page-component-77c89778f8-gvh9x Total loading time: 0 Render date: 2024-07-19T22:45:36.544Z Has data issue: false hasContentIssue false
  • English
  • Français

Canadian Consensus Conference on Dementia: Two Years Later

Published online by Cambridge University Press:  02 December 2014

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Other
Information
Canadian Journal of Neurological Sciences , Volume 28 , Supplement S1: Canadian Consensus Conference on Dementia , May 2001 , pp. S1 - S2
Copyright
Copyright © The Canadian Journal of Neurological 2001

References

1. Petersen, RC, Smith, GE, Waring, SC. Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol. 1999; 56: 303–308.Google Scholar
2. Ritchie, K, Touchon, J. Mild cognitive impairment: conceptual basis and current nosological status. Lancet 2000; 355: 225–228.Google Scholar
3. Blacker, D, Tanzi, RE. The genetics of Alzheimer disease. Arch Neurol 1998; 55: 294–296.Google Scholar
4. Munoz, DG, Feldman, H. Causes of Alzheimer’s disease. CMAJ 2000; 162: 65–72 Google Scholar
5. Corey-Bloom, J, Anand, R, Vach, J for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatric Psychopharmacol 1998; 1: 55–65.Google Scholar
6. Rosler, M, Anand, R, Cicin-Sain, A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s Disease: international randomised controlled trial. Br Med J 1999; 318 (7184):633–638.Google Scholar
7. Raskind, MA, Peskind, ER, Wessel, T, Yuan, W, and the Galantamine USA-1 Study Group. Galantamine in AD. A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261–2268.Google Scholar
6. Tariot, PN, Solomon, PR, Morris, JC, Kershaw, P, Lilienfeld, S, Ding, C, and the Galantamine USA-10 Study Group. A 5-month randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269–2276.Google Scholar
9. Feldman, H, Gauthier, S, Hecker, J, Vellas, B, Subbiah, P, Whalen, E, and the Donepezil MSAD Study Group. Benefits of donepezil on global function, behaviour, cognition, and ADLs in patients with moderate-to-severe Alzheimer’s disease. Neurology 2000; 54(3); A469.Google Scholar
10. Shea, C, Macknight, C, Rockwood, K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patient. Int Psychogeriatr 1998; 10(3): 229–238.Google Scholar
11. De Deyn, PP, Rabheru, K, Rasmussen, A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioural symptoms of dementia. Neurology 1999; 53:946–955.Google Scholar
12. Katz, IR, Jeste, DV, Mintzer, JE, et al. Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry 1999; 60:107–115.Google Scholar
13. Defilippi, JL, Crismon, ML. Antipsychotic agents in patients with dementia. Pharmacotherapy 2000; 20(S1): 23–33.Google Scholar